Vivoryon Therapeutics N.V. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was EUR 28.16 million compared to EUR 12.66 million a year ago. Basic loss per share from continuing operations was EUR 1.28 compared to EUR 0.63 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8 EUR | -2.44% | +76.60% | -90.17% |
Apr. 24 | Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024 | |
Mar. 15 | Vivoryon Therapeutics N.V Announces Resignation of Board of Directors | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-90.17% | 22.26M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- VVY Stock
- News Vivoryon Therapeutics N.V.
- Vivoryon Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2022